Rein Therapeutics RNTX Income Statement (2016-2026)

NASDAQ RNTX
$0.79 +0.00 (+0.00%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
4.53M4.53M4.54M4.54M4.54M4.54M4.54M4.54M4.54M4.89M8.30M21.63M21.67M17.94M22.01M23.05M25.14M27.55M28.04M67.08M
Operating items
Research & Development (Quarter)
4.28M4.56M5.89M5.43M4.24M2.40M1.81M0.19M0.02M1.97M3.46M3.74M3.72M3.32M3.05M4.29M1.68M2.00M3.07M3.64M
Selling, General & Administrative (Quarter)
2.51M2.25M2.53M2.61M2.24M2.30M2.18M1.89M1.96M5.33M3.74M5.30M2.35M2.48M2.56M2.58M3.81M1.96M2.16M2.44M
Restructuring Costs (Quarter)
1.02M-0.09M0.01M-0.01M
Other Operating Expenses (Quarter)
37.00M28.70M
Operating Expenses (Quarter)
6.79M6.82M8.42M8.04M6.48M4.70M5.01M1.99M1.98M7.29M7.21M9.04M6.07M42.80M5.61M6.87M5.49M32.66M5.23M6.08M
Operating Income (Quarter)
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
EBIT (Quarter)
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Non-operating items
Interest & Investment Income (Quarter)
-0.01M-0.01M-0.06M-0.03M0.00M0.05M0.04M0.01M0.00M0.04M-0.00M0.01M-0.04M0.01M0.02M-0.01M
Other Non Operating Income (Quarter)
0.07M0.07M-0.02M0.00M0.34M0.23M0.20M0.16M-0.05M0.09M0.10M0.22M0.27M0.11M0.05M-0.09M-0.02M-0.61M-0.30M
Non Operating Income (Quarter)
0.02M0.02M0.05M0.11M0.06M0.11M0.15M
Net income details
EBT (Quarter)
-7.24M-76.51M-8.56M-8.17M-6.58M-82.09M-4.98M-1.99M-1.98M-25.80M-16.10M-11.30M-9.45M-73.24M-6.57M-7.31M-5.64M-32.80M-5.55M-6.55M
Profit After Tax (Quarter)
-0.01M19.35M-8.42M-7.99M-6.37M-27.28M-4.78M-1.79M0.00M-0.06M-7.11M-8.94M-5.85M-40.94M-0.01M-6.82M-5.58M-0.02M-5.84M-6.38M
Income from Continuing Operations (Quarter)
-7.24M-76.51M-8.56M-8.17M-6.58M-82.09M-4.98M-1.99M-1.98M-25.80M-16.10M-11.30M-9.45M-73.24M-6.57M-7.31M-5.64M-32.80M-5.55M-6.55M
Consolidated Net Income (Quarter)
-7.24M-76.51M-8.56M-8.17M-6.58M-82.09M-4.98M-1.99M-1.98M-25.80M-16.10M-11.30M-9.45M-73.24M-6.57M-7.31M-5.64M-32.80M-5.55M-6.55M
Income towards Parent Company (Quarter)
-7.24M-76.51M-8.56M-8.17M-6.58M-82.09M-4.98M-1.99M-1.98M-25.80M-16.10M-11.30M-9.45M-73.24M-6.57M-7.31M-5.64M-32.80M-5.55M-6.55M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-7.24M-76.51M-8.56M-8.17M-6.58M-82.09M-4.98M-1.99M-1.98M-25.80M-16.10M-11.30M-9.45M-73.24M-6.57M-7.31M-5.64M-32.80M-5.55M-6.55M
Additional items
EPS (Basic) (Quarter)
-1.60-17.23-1.89-1.80-1.45-18.09-1.10-0.44-0.44-5.61-1.94-0.57-0.44-4.08-0.30-0.30-0.21-1.29-0.18-0.10
EPS (Diluted) (Quarter)
-1.60-17.23-1.89-1.80-1.45-18.09-1.10-0.44-0.44-5.61-1.94-0.57-0.44-4.08-0.30-0.30-0.21-1.29-0.18-0.10
Shares Outstanding (Quarter)
4.53M4.44M4.53M4.54M4.54M4.54M4.54M4.54M4.54M4.60M8.30M19.91M21.66M17.94M21.92M24.19M26.36M25.44M30.35M67.08M
Shares Outstanding (Diluted) (Quarter)
4.53M4.44M4.53M4.54M4.54M4.54M4.54M4.54M4.54M4.60M8.30M19.91M21.66M17.94M21.92M24.19M26.36M25.44M30.35M67.08M
EBITDA (Quarter)
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Interest Expenses (Quarter)
0.44M69.68M0.07M0.10M0.10M77.44M0.01M0.00M18.51M8.89M2.31M3.38M30.45M0.91M0.45M0.15M0.16M0.32M0.46M